The BEAT CARDIO SYMPOSIUM 2023, organised by Laketown Synergy, was a highly anticipated medical conference aimed at providing valuable insights into the management of acute and chronic heart failure with a focus on timely intervention. Held on 23rd July 2023 at Hotel Hindustan International, Kolkata, the symposium brought together esteemed members of the medical fraternity to discuss the latest advancements in cardiovascular care, particularly in the context of diabetes-related issues. This blog post will provide a detailed overview of the event, highlighting key topics and discussions covered during the symposium.
The Distinguished Speakers
The symposium boasted an impressive lineup of speakers, each a prominent figure in the field of cardiology. Dr. Bijay P. Pandey, DM (Cardiology) at Narayana Superspeciality Hospital, Howrah, Kolkata, took on the role of Moderator for the Panel Discussion. Dr. Debashish Ghosh, Sr. Consultant, Dept. of Interventional Cardiology at Apollo Multi-speciality Hospital, Kolkata, discussed SGLT2-i (Sodium-Glucose Cotransporter 2 inhibitors) in Cardiology, exploring discoveries from EMPA-REG OUTCOME to EMPACT MI. Dr. Sunil Lhila, Senior Consultant in Interventional Cardiology at Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, shared insights into Pre-discharge initiation of HF (Heart Failure) therapies, focusing on EMPULSE and the state of the art approaches.
Dr. Sunip Banerjee, an Independent Interventional Cardiologist at Ruby General Hospital, Kolkata, presented the topic “Transcending LVEF Classification in HF Care,” delving into the significance of EMPEROR-Preserved and its implications. Dr. Dilip Kumar, Director of Cath Lab and Senior Interventional Cardiologist at Medica Super Specialist Hospital, Kolkata, discussed the potential of SGLT2-i in the prevention of HF post AMI (Acute Myocardial Infarction), highlighting a silver lining in diabetes care.
Exploring SGLT2-i in Cardiology
The symposium’s primary focus was the role of SGLT2-i in cardiovascular care, particularly for patients with diabetes. The discussions began with Dr. Debashish Ghosh’s presentation, where he shed light on the journey of SGLT2-i from the EMPA-REG OUTCOME trial to EMPACT MI. The emerging evidence from clinical trials showcased the potential of these inhibitors in reducing cardiovascular mortality and hospitalisation rates among diabetic patients.
Advancing Heart Failure Therapies
The symposium also covered advancements in HF therapies, with a special emphasis on the EMPULSE study. Dr. Sunil Lhila’s presentation highlighted the significance of pre-discharge initiation of HF therapies, which can significantly improve patient outcomes and reduce readmission rates. The symposium provided valuable insights into the state-of-the-art approaches in managing heart failure, benefitting both physicians and patients.
Beyond LVEF Classification in HF Care
Dr. Sunip Banerjee’s talk centered on transcending LVEF (Left Ventricular Ejection Fraction) classification in HF care, with a focus on EMPEROR-Preserved. This research has challenged conventional thinking and opened new avenues for tailoring therapies based on individual patient characteristics, ultimately leading to improved treatment outcomes for HF patients.
Potential Role of SGLT2-i in HF Prevention Post AMI
Dr. Dilip Kumar’s presentation added to the growing excitement around SGLT2-i by exploring their potential role in preventing HF post AMI. The discussion highlighted how these inhibitors could offer a promising approach to managing cardiovascular complications in diabetic patients after experiencing a heart attack.
Panel Discussion: SGLT2-i and a Cardiologist
The symposium concluded with a dynamic panel discussion moderated by Dr. Bijay P. Pandey. The panelists engaged in an interactive session, sharing their experiences and knowledge on when, how, and why to incorporate SGLT2-i into their practice. The discussion aimed to provide a comprehensive understanding of the practical implications of these inhibitors and their integration into existing treatment paradigms.
Conclusion
The BEAT CARDIO SYMPOSIUM 2023 proved to be an invaluable platform for the medical fraternity to explore the latest developments in cardiac care with a focus on SGLT2-i in diabetes patients. The event provided medical practitioners with essential insights into timely interventions for acute and chronic heart failure, ultimately leading to better patient outcomes. As the symposium successfully wrapped up, it left attendees inspired and armed with cutting-edge knowledge to drive advancements in cardiovascular care. For potential sponsors, this symposium serves as a testament to the need for continued support in organising future events that foster meaningful discussions and innovations in the field of cardiology.